Introduction: Thrombocytopenia in chronic liver disease - Treatment implications and novel approaches

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 1-4

  Afdhal, N H ^a   Esteban, R ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ELTROMBOPAG; GROWTH FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERFERON; INTERLEUKIN 11; PEPTIDE DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THROMBOPOIETIN;

ANEMIA; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION REACTION; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; INFECTION COMPLICATION; NEUTROPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BLOOD COAGULATION DISORDERS; CHRONIC DISEASE; HUMANS; LIVER DISEASES; PATIENT CARE MANAGEMENT; PLATELET COUNT; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 35448955576     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03508.x     Document Type: Review

References (28)

1. Bashour FN, Teran C, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic lvier disease. Am J Gastroenterol 2000 95 : 2936 9.
2. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Alim Pharmacol Ther 2006 23 : 1055 65.
3. Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982 4 : 451 3.
4. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990 94 : 747 53.
5. Williford SK, Salisbury PL III., Peacock JE Jr., et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989 7 : 798 802.
6. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003 37 : 533 41.
7. Murphy MF, Waters AH. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991 2 : 389 96.
8. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 64.
9. Kaushansky K. Thrombopoietin. N Engl J Med 1998 339 : 746 54.
10. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001 113 : 590 5.
11. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000 14 : 1009 31.
12. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60D 6D.
13. Jabbour N, Zajko A, Orons P, Dod WI, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998 43 : 2459 62.
14. Wang C, Yao W, Wang A, Chang T, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004 39 : 790 6.
15. Zimmermann T, Böcher WO, Biesterfeld S, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribiviran in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007 20 : 583 90.
16. Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006 20 : 589 92.
17. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver DIs 2005 9 : 439 51, vii.
18. Kajiwara E, Akagi K, Azuma K, Onoyama K, Fujishima M. Evidence for an immunological pathogenesis of thrombocytopenia in chronic liver disease. Am J Gastroenterol 1995 90 : 962 6.
19. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2002 325 : 135 48.
20. Ali A, Zein NN. Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med 2005 72 : 1005 19.
21. Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001 85 : 667 70.
22. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003 38 : 230 7.
23. Tacke F, Fiedler K, von Depka M, et al. Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease. Liver Int 2006 26 : 173 81.
24. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol 1990 17 : 198 209.
25. Bonkovsky HL, Woolley JM. Outcomes research in chronic viral hepatitis C: effects of interferon therapy. Can J Gastroenterol 2000 14 (Suppl. B 21B 9B.
26. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care 2005 11 (Suppl. S296 306.
27. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001 6 (Suppl. 5 15 23.
28. McHutchison JG, Afdahl N, Shiffman ML, et al. Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: preliminary results from a Phase II multicenter, randomised, placebo controlled, double-blind, dose-ranging study [Abstract]. Presented at Digestive Disease Week, May 20-25, 2006, Los Angeles, Calif A338).